By CERBIOS-PHARMA SA
Cerbios-Pharma named as Europe’s Top CMO for 2022
Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) has received the award for Europe’s Top CMO/CDMO (Contract Development Manufacturing Organization) for 2022 from Pharma Tech Outlook magazine.
The US-based online journal announces the award in its April 2022 CMO Edition, featuring the company’s Chief Commercial Officer Denis Angioletti on the cover.
One stop shop advantage
The cover story explains why Cerbios is a front-runner in HPAPIs and ADCs arena owing to its unique ability to offer the development and manufacturing of ADC and all its components (mAb, toxin/payload, conjugate) in a single site.
Acknowledging that the pharma landscape is ‘is brimming with innovative CDMOs offering R&D and production capabilities across all stages of drug development’, the magazine points out that most only handle specific facets of the overall development and manufacturing of a product, compelling drug manufacturers to collaborate with multiple vendors.
“Particularly in process development, scale up, and industrial production of APIs and their derivatives, drug developers find themselves between a rock and a hard place because the current CDMO arena lacks a partner with the proven ability to safely perform chemical and analytical processes on sensitive and costly molecules.
End-to-end ADC services
The magazine’s editorial board singled out Cerbios-Pharma for its distinctive ability to offer a true one-stop shop service.
“The company combines process development with manufacturing capabilities to provide a truly end-to-end service that improves effectiveness without compromising the speed and efficiency of clinical trials. Cerbios further expands its ADC services with its PROVEO division that extends the capacity for mAbs (at AGC Bio) and fill-finish services (at Oncotec),” the article notes.
“From a production standpoint, the company has two fully independent cGMP manufacturing facilities for cytotoxic and non-cytotoxic bioconjugates with 5L-200L single-use reactors, bioburden controlled processes, and dedicated freezing equipment to facilitate effective lyophilizations and drive zero wastage, faster production, and higher cost-savings,” it adds.
Mr. Angioletti commented: “We thank Pharma Tech Outlook for giving us the possibility to share with the magazine readers more about Cerbios and its long term strategy in the CDMOs scenario, started in 2000 with the first production of an HPAPI and now still proceeding with investments both on HPAPIs and ADCs.”
Cerbios is a privately held company located in Lugano, Switzerland, specialized in manufacturing Pharma Products and in offering CDMO services.
Cerbios is the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Proveo (TM) is a Cerbios division recently created to provide end-to-end development and manufacturing services for ADCs.
Cerbios is also a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders. Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response.
Learn more at: https://cerbios.swiss
Click on Pharma Tech Outlook CMO Europe edition to read full article.